EGFR and non-small cell lung carcinoma: In two recent trials in advanced non-small cell lung cancer, therapy with gefitinib administered in a genotype-directed fashion to patients harbouring EGFR mutations resulted in very favourable clinical outcomes with good tolerance (Sequist et al, 2008; Tamura et al, 2008).